Are the common side effects of Lazertinib easy to control and alleviate?

As a third-generation EGFR mutation-positive non-small cell lung cancer (NSCLC) targeted drug, Lazertinib has generally controllable side effects and is well tolerated by most patients. According to clinical trial data, the most common adverse reactions include rash, diarrhea, oral ulcers, fatigue, etc., most of which are mild to moderate and belong to the typical side effects spectrum of targeted drug therapy. The incidence is relatively predictable and facilitates early intervention.

Skin-related side effects such as rash and itching are common and usually occur early in the treatment. Most patients can be relieved by using topical hormone ointments, anti-allergy drugs, and avoiding sun exposure. Severe cases may require a short-term suspension of medication or adjustment of dosage. Doctors generally inform these risks in advance and give patients detailed care instructions, so that most patients can continue treatment without affecting the efficacy.

Gastrointestinal adverse reactions, such as diarrhea and nausea, usually occur early in the treatment. Most of these side effects are mild to moderate and can be controlled by taking antidiarrheal drugs, adjusting diet, and increasing water intake. Some patients' symptoms can resolve on their own after taking the medication for several weeks, and they are less likely to be forced to discontinue medication due to diarrhea and other problems, indicating that such side effects are easier to manage.

Overall, the side effects of lanzetinib are not difficult to manage and are mostly reversible. During the course of treatment, regular review and communication with the doctor are key. Once serious discomfort occurs, intervention can also be carried out through dose adjustment or combined supportive care. Most patients can successfully complete the treatment course under professional guidance, so lanzitinib has shown high safety and compliance in actual clinical use.

Reference materials:https://www.drugs.com/